Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study.
Kohei KakuKazuhiro YamamotoYumiko FukushimaHristo LlievAtsutaka YasuiPublished in: Expert opinion on drug safety (2022)
Empagliflozin is effective and generally well tolerated in Japanese patients, and ADRs are consistent with its known safety profile.